Abbott today announced
results from a post-hoc analysis of HUMIRA^® (adalimumab) data in early and
long-standing moderate-to-severe rheumatoid arthritis (RA) patients from three
randomized, controlled trials—DE019, OPTIMA and PREMIER. The analysis
evaluated the simultaneous achievement of three key treatment goals: low
disease activity, normal physical function and the absence of radiographic
progression at one year. These results are being presented at the American
College of Rheumatology Annual Scientific Meeting (ACR) in Washington, D.C.
In the analysis, low disease activity was measured by the Disease Activity
Score 28 based on C reactive protein [DAS28 (CRP)], less than 3.2; normal
function was measured by the Health Assessment Questionnaire for RA Disability
Index [HAQ-DI], less than 0.5; and the absence of radiographic progression was
demonstrated by a change in modified Total Sharp Score [mTSS], less than or
equal to 0.5 at one year.
- Reduction of disease activity, prevention of further joint damage and
preservation of physical function were the three goals evaluated
- Data analysis for long-standing RA patients showed 19 percent of patients
taking HUMIRA plus methotrexate (MTX) simultaneously achieved all three goals
at one year, versus 5 percent of patients treated with placebo plus MTX
- Data analysis for early RA patients —those who received open label HUMIRA
plus MTX following inadequate response to 26 weeks of MTX monotherapy—showed
29 percent simultaneously achieved all three goals at one year
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in